FDA approves revised medication guide for Coumadin

Share this article:
The FDA has approved a revised medication guide and labeling for Bristol-Myers Squibb's blood thinner Coumadin (warfarin sodium) to more prominently emphasize a warning about the risk of major or fatal bleeding.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.